Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study

Phase 3positivePositive

AI Analysis

Summary

Amgen's investigational Sjögren's disease therapy, acquired from the $27.8B Horizon Therapeutics purchase, achieved positive results in a Phase 3 trial. The company is awaiting another Phase 3 readout later in 2026, with analysts anticipating at least two trials will be needed to support FDA application.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 3 trial scored in Sjögren's disease study

Importance:7/10

Sentiment:

0.70

Phase 3Sjögren's diseaseAmgenHorizon Therapeuticsclinical trialacquisition asset

Related Companies

$AMGN $HZNP

Read the original article

Published by BioSpace on September 23, 2026 1:50 PM

Read Original